Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jingjing Zhao
Observed name:
Jing-Jing Zhao
Institutions:
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
Observed institutions:
Sun Yat-sen University,
Henan University of Chinese Medicine,
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
ORCID:
0000-0002-5089-7608
Observed ORCID:
0000-0002-5089-7608
OpenAlex ID:
A5030496984
EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion
2024
·
Yuanyuan Chen
, Dijun Ouyang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
55
Transformable Tumor Microenvironment‐Responsive Oxygen Vacancy‐Rich MnO 2 @Hydroxyapatite Nanospheres for Highly Efficient Cancer Sonodynamic Immunotherapy
2025
·
Minxing Li
, Qiyu Liu
, et al.
·
Advanced Science
·
22
Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma
2024
·
Xinyi Yang
, Yuanyuan Liu
, et al.
·
Molecular Cancer Therapeutics
·
15
The CXCL10‐CXCR3 Axis Induces Tumor‐Associated Neutrophils to Interfere with CTLs‐Mediated Antitumor Activity in EBV‐Associated Epithelial Cancers
2025
·
Dijun Ouyang
, Tong Xiang
, et al.
·
Advanced Science
·
14
SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity
2024
·
Nan Fang
, Bing Liu
, et al.
·
Molecular Cancer Therapeutics
·
6
[Mechanism of Mahuang Lianqiao Chixiaodou Decoction in treating eczema by network pharmacology and molecular docking technology].
2021
·
Xiao-Wen Zhang
, Ai-Min Liu
, et al.
·
PubMed
·
6
Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population
2024
·
Yuanyuan Liu
, Xinyi Yang
, et al.
·
BMC Cancer
·
3
PDF
Data from SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity
2024
·
Nan Fang
, Bing Liu
, et al.
·
1
Supplementary Table S4 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S6 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S7 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S4 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S3 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S2 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S3 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S5 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S2 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Data from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S5 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S1 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S1 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
·
Clinical Cancer Research
Figure S1 from Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma
2026
·
Xinyi Yang
, Yuanyuan Liu
, et al.
Figure S3 from Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma
2026
·
Xinyi Yang
, Yuanyuan Liu
, et al.
Figure S2 from Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma
2026
·
Xinyi Yang
, Yuanyuan Liu
, et al.
Show more works
View as search
Works count:
34
Citation count:
122
H-index:
6
I10-index:
4
Year
Topic
Type